We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
Read MoreHide Full Article
Key Takeaways
Veeva Systems' DQS has cleaned data for over 1 million subjects across more than 1,000 clinical studies.
DQS generated over 500,000 automated queries, reducing manual effort in reconciling clinical trial data.
AI, CTMS integration and Study Builder Agent expand DQS automation across clinical data workflows.
Veeva Systems (VEEV - Free Report) continues to strengthen its position in the life sciences software market as its Veeva DQS (Data Quality System) platform expands its reach across clinical trials. The company said that the solution has now supported data cleaning across more than 1,000 studies involving over 1 million subjects, highlighting growing adoption of its clinical data management capabilities.
The expanding scale of Veeva DQS is encouraging as biopharma companies increasingly prioritize efficient data management amid rising clinical trial complexity. Broader adoption of the platform could support deeper customer engagement, reinforce Veeva’s position in clinical software and create additional opportunities for recurring revenue growth over the long term.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of VEEV traded flat in yesterday’s market. Year to date, shares of the company have gained 27% compared with the industry’s 17.5% growth. However, the S&P 500 has risen 14.6% in the same timeframe.
Veeva DQS’ growing adoption could support Veeva’s long-term business by strengthening its footprint in clinical data management and increasing the value of its broader R&D platform. As sponsors and CROs manage larger volumes of complex clinical data, demand for automated and integrated data solutions is likely to rise.
Wider use of DQS can deepen Veeva’s relationships with existing customers, create cross-selling opportunities across its clinical applications and improve customer retention. Over time, this could contribute to more predictable recurring revenues while reinforcing Veeva’s competitive position in the life sciences software market.
VEEV currently has a market capitalization of $45.89 billion.
Image Source: Zacks Investment Research
Veeva DQS Expands Automation Across Clinical Data Management
Veeva DQS has now aggregated and cleaned clinical trial data for more than 1 million subjects across more than 1,000 studies, underscoring the platform’s ability to operate at scale as clinical trials generate increasingly large and complex datasets. The system has also generated more than 500,000 automated queries, helping sites and sponsors reduce the manual effort involved in reconciling trial data and accelerating the availability of analysis-ready information. Adoption by sponsors and CROs across studies of different sizes provides a tangible indication of the platform’s growing role in modern clinical data management.
A key growth opportunity for Veeva DQS lies in its ability to connect clinical data management more closely with broader trial operations and emerging risk-based approaches. The platform supports automated data exchange with Veeva CTMS, enabling teams to identify changes such as protocol deviations and track key risk indicators as part of risk-based quality management.
DQS also incorporates AI to classify study data based on its purpose and criticality, potentially reducing repetitive work for clinical data teams. In addition, Veeva’s recently introduced Study Builder Agent is designed to configure Veeva EDC and DQS directly from study protocols, further connecting study setup with downstream data management. Together, these developments could increase the strategic importance of DQS within Veeva’s clinical platform and strengthen customer reliance on its integrated suite of applications.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
Recently, Veeva announced that Servier has selected Veeva OpenData to standardize customer reference data across more than 80 countries. The move strengthens Veeva’s position as a key provider of data solutions for global life sciences companies.
The deal underscores growing demand for high-quality, connected data as pharmaceutical companies look to scale artificial intelligence and advanced analytics.
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
Key Takeaways
Veeva Systems (VEEV - Free Report) continues to strengthen its position in the life sciences software market as its Veeva DQS (Data Quality System) platform expands its reach across clinical trials. The company said that the solution has now supported data cleaning across more than 1,000 studies involving over 1 million subjects, highlighting growing adoption of its clinical data management capabilities.
The expanding scale of Veeva DQS is encouraging as biopharma companies increasingly prioritize efficient data management amid rising clinical trial complexity. Broader adoption of the platform could support deeper customer engagement, reinforce Veeva’s position in clinical software and create additional opportunities for recurring revenue growth over the long term.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of VEEV traded flat in yesterday’s market. Year to date, shares of the company have gained 27% compared with the industry’s 17.5% growth. However, the S&P 500 has risen 14.6% in the same timeframe.
Veeva DQS’ growing adoption could support Veeva’s long-term business by strengthening its footprint in clinical data management and increasing the value of its broader R&D platform. As sponsors and CROs manage larger volumes of complex clinical data, demand for automated and integrated data solutions is likely to rise.
Wider use of DQS can deepen Veeva’s relationships with existing customers, create cross-selling opportunities across its clinical applications and improve customer retention. Over time, this could contribute to more predictable recurring revenues while reinforcing Veeva’s competitive position in the life sciences software market.
VEEV currently has a market capitalization of $45.89 billion.
Image Source: Zacks Investment Research
Veeva DQS Expands Automation Across Clinical Data Management
Veeva DQS has now aggregated and cleaned clinical trial data for more than 1 million subjects across more than 1,000 studies, underscoring the platform’s ability to operate at scale as clinical trials generate increasingly large and complex datasets. The system has also generated more than 500,000 automated queries, helping sites and sponsors reduce the manual effort involved in reconciling trial data and accelerating the availability of analysis-ready information. Adoption by sponsors and CROs across studies of different sizes provides a tangible indication of the platform’s growing role in modern clinical data management.
A key growth opportunity for Veeva DQS lies in its ability to connect clinical data management more closely with broader trial operations and emerging risk-based approaches. The platform supports automated data exchange with Veeva CTMS, enabling teams to identify changes such as protocol deviations and track key risk indicators as part of risk-based quality management.
DQS also incorporates AI to classify study data based on its purpose and criticality, potentially reducing repetitive work for clinical data teams. In addition, Veeva’s recently introduced Study Builder Agent is designed to configure Veeva EDC and DQS directly from study protocols, further connecting study setup with downstream data management. Together, these developments could increase the strategic importance of DQS within Veeva’s clinical platform and strengthen customer reliance on its integrated suite of applications.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
Recently, Veeva announced that Servier has selected Veeva OpenData to standardize customer reference data across more than 80 countries. The move strengthens Veeva’s position as a key provider of data solutions for global life sciences companies.
The deal underscores growing demand for high-quality, connected data as pharmaceutical companies look to scale artificial intelligence and advanced analytics.
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.